One-Upping Cancer: An Oncodesign Services – ImaginAb Collab

An interesting partnership with ImaginAb Inc. has been announced by Oncodesign Services, a renowned Contract Research Organization (CRO) with expertise in oncology and immuno-inflammation medication discovery and preclinical services. Through this collaboration, Oncodesign Services will have access to ImaginAb’s ground-breaking CD8 ImmunoPET^TM (89Zr crefmirlimab berdoxam) experimental technology. Modern PET imaging technology like CD8 ImmunoPET^TM makes it possible to see the immune system, which may be useful for radiopharmaceutical and immunotherapy treatments.

Visualizing the Immune System: CD8 ImmunoPET^TM

With the ability to effectively target and eliminate cancer cells, immunotherapy has revolutionized the way cancer is treated. Oncodesign Services intends to use ImaginAb’s CD8 ImmunoPET^TM technology in preclinical investigations to enhance the comprehension and predicted efficacy of novel immunotherapies and radioimmunotherapy.

An novel 89Zr-labeled micro body called CD8 ImmunoPET^TM is made to attach to the CD8 receptor on human T cells. This approach enables quantitative visualization and tracking of immunological T CD8 cells throughout the body using non-invasive PET imaging. Scientists can learn important things about customized medicine by figuring out how immunotherapies affect the immune system and evaluating their potential usefulness.

Advancing Preclinical Studies

Oncodesign Services’ inclusion of CD8 ImmunoPET^TM in their portfolio signifies a significant stride in bridging the gap between the preclinical and clinical stages of drug development. This technology is expected to enhance the company’s services by providing a dynamic follow-up of immune T CD8 cells in their preclinical models. This real-time monitoring of the immune response can lead to a deeper understanding of treatment effectiveness, ultimately helping to develop more efficient therapies for cancer patients.

A Promising Partnership

Fabrice Viviani, President & Chief Executive Officer of Oncodesign Services, expressed his excitement about integrating this groundbreaking technology into their research. The CD8 ImmunoPET^TM offering holds the potential to revolutionize the way preclinical studies are conducted, aiding in the evaluation of novel immunotherapies’ efficacy and predicting patient outcomes. Oncodesign Services is dedicated to advancing its knowledge and capabilities in the era of personalized medicine.

Ian Wilson, Chief Executive Officer of ImaginAb, also sees great promise in the partnership. He believes that pharmaceutical and biotech companies can greatly benefit from using CD8 ImmunoPET^TM to better understand the potential efficacy of their pipeline therapeutic products during preclinical studies. The hope is that this collaboration will lead to more effective and targeted therapies in the field of immunotherapy.

Oncodesign Services’ collaboration with ImaginAb and their access to CD8 ImmunoPET^TM technology opens up new possibilities in preclinical studies. This innovative imaging technology has the potential to revolutionize the evaluation of immunotherapies and radioimmunotherapies, enabling researchers to gain valuable insights into treatment effectiveness and paving the way for personalized medicine. This partnership between Oncodesign Services and ImaginAb holds promise for the future of cancer treatment and therapeutic development.

About ImaginAb

Through its exclusive minibody and cys-diabody platforms, the multinational biotechnology business ImaginAb Inc. is focused on creating radiopharmaceutical therapeutic solutions and the next generation of imaging agents. A number of pharmaceutical and biotech businesses have granted licenses for the use of their lead candidate, CD8 ImmunoPET^TM, in clinical trials for immunotherapy. CD8 ImmunoPET^TM is currently in Phase II clinical trials.

Learn more from imaginab.com.

About CD8 ImmunoPETTM (89Zr crefmirlimab berdoxam)

A revolutionary 89Zr-labeled minibody called CD8 ImmunoPET^TM was created to connect to the CD8 receptor on human T cells and enable quantitative, non-invasive PET imaging. Research on the technology is being done to determine the immunological status of patients, evaluate the effectiveness of immunotherapies, and forecast patient outcomes, among other uses.

Learn more from imaginab.com/products/cd8-immunopet.

About Oncodesign Services

One of the top CROs, Oncodesign Services, focuses on drug discovery and preclinical services for cancer and immuno-inflammation. Oncodesign Services provides a full spectrum of services, from target selection to IND application, with experience in a variety of domains including Medicinal Chemistry, Pharmacology, Pharmaco-Imaging, and more. The organization, which has over 225 people throughout France, Canada, and the US, is dedicated to expanding drug development and enhancing patient outcomes.

Visit this site to learn more: oncodesign-services.com.

Engr. Dex Marco Tiu Guibelondo, BS Pharm, RPh, BS CpE

Editor-in-Chief, PharmaFEATURES